NUC-7738 is a phosphoramidate prodrug of 3-deoxyadenosine designed to overcome resistance mechanisms. It inhibits beta-catenin signaling by reducing its nuclear expression in AML cells, showing potential for cancer research in both in vitro and in vivo models.
